FrancophonIA/ELRC3.0 huggingface dataset:
English: Gilts are animals which have produced fewer than two litters.
Estonian: Nooremised on sead, kes on poeginud vähem kui kaks korda.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) considered that, in accordance with European Union requirements, Neocolipor had been shown to be effective in the reduction of neonatal enterotoxicosis in piglets.
Estonian: Veterinaarravimite komitee leidis, et Euroopa Liidu nõuete kohaselt on Neocolipori tõhusus põrsaste neonataalse enterotoksikoosi vähendamisel tõendatud.
English: Safety data were also presented for the recommended use of the product both under laboratory conditions and in the field.
Estonian: Lisaks esitati ohutusandmed ravimi soovitatava kasutamise kohta nii labori- kui ka välitingimustes.
English: The vaccine is intended for use 5-7 weeks before the birth of the litter (farrowing) with a second vaccination at 2 weeks prior to farrowing.
Estonian: Vaktsiini tuleb manustada 5-7 nädalat enne poegimist ning teist korda tuleb vaktsineerida 2 nädalat enne poegimist.
English: A booster vaccination is given 2 weeks prior to each subsequent farrowing.
Estonian: Seejärel revaktsineeritakse loomi kaks nädalat enne igat järgnevat poegimist.
English: A number of trials were carried out in both the laboratory and in the field in order to assess the efficacy of the product.
Estonian: Ravimi tõhususe hindamiseks korraldati mitu labori- ja väliuuringut.
English: This summary was last updated in August 2008.
Estonian: Kokkuvõtte viimane uuendus: 08-2008.
English: Vaccination of the mother animal (sows and gilts) enables the offspring to receive a passive immunity during their first days of life against neonatal enterotoxicosis caused by E. coli strains carrying the adhesins F4, F5, F6 and F41.
Estonian: Vaktsiini manustamine emasloomadele (emistele ja nooremistele) annab nende järglastele nende esimestel elupäevadel passiivse immuunsuse adhesiine F4, F5, F6 ja F41 kandvate E. coli tüvede põhjustatud neonataalse enterotoksikoosi vastu.
English: Re-vaccination was shown to be effective at the intervals recommended.
Estonian: Tõendati soovitatud ajavahemike järel revaktsineerimise tõhusust.
English: Neocolipor is an inactivated vaccine intended to be used to reduce neonatal enterotoxicosis (a bacterial infection caused by strains of E.coli) in very young piglets.
Estonian: Neocolipor on inaktiveeritud vaktsiin, mida kasutatakse väga noortel põrsastel neonataalse enterotoksikoosi (E. coli tüvede põhjustatud bakternakkuse) vähendamiseks.
English: Why has Neocolipor been approved?
Estonian: Miks Neocolipor heaks kiideti?
English: Other information about Neocolipor:
Estonian: Muu teave Neocolipori kohta
English: What is Neocolipor?
Estonian: Mis on Neocolipor?
English: Neocolipor is administered to female pigs - both sows and gilts - in order to immunise their offspring against neonatal enterotoxicosis.
Estonian: Neocolipori manustatakse nii emistele kui nooremistele, et immuniseerida nende järglasi neonataalse enterotoksikoosi vastu.
English: How does Neocolipor work?
Estonian: Kuidas Neocolipor toimib?
English: What are the side-effects of Neocolipor?
Estonian: Millised on Neocolipori kõrvalnähud?
English: What is Neocolipor used for?
Estonian: Milleks Neocolipori kasutatakse?
English: What benefit has Neocolipor shown during the studies?
Estonian: Milles seisneb uuringute põhjal Neocolipori kasulikkus?
English: How has Neocolipor been studied?
Estonian: Kuidas Neocolipori uuriti?
English: <EMA procedure number> <MA (EU) number> (Invented) name Strength Pharmaceutical form Route of administration Immediate Packaging <Content (concentration)> Pack size
Estonian: <EMA protseduuri number> <Müügiloa nr Euroopa Liidus> (Väljamõeldud) nimetus Tugevus Ravimvorm Manustamistee Sisepakendi iseloomustus <Pakendi sisu (kontsentratsioon)> Pakendi suurus
English: 3 - How to take Keppra
Estonian: 3 - Kuidas ravimit Keppra kasutada
English: Keppra must be taken twice a day, once in the morning and once in the evening, at about the same time each day.
Estonian: Ravimit Keppra tuleb võtta kaks korda ööpäevas, üks kord hommikul ja üks kord õhtul, enam-vähem samal ajal iga päev.
English: Tell your doctor immediately and stop taking metronidazole if you develop:
Estonian: Rääkige kohe oma arstile ja lõpetage metronidasooli võtmine, kui teil tekib:
English: After measuring the correct dose with an appropriate syringe, Keppra oral solution may be diluted in a glass of water or baby's bottle.
Estonian: Pärast õige annuse välja mõõtmist sobiva süstlaga võib Keppra suukaudset lahust lahjendada klaasitäie veega või imiku joogipudelis.
English: In this population, metronidazole should therefore be used after careful benefit-risk assessment and only if no alternative treatment is available.
Estonian: Seetõttu tohib selles patsiendipopulatsioonis metronidasooli kasutada ainult pärast kasulikkuse ja riski hoolikat hindamist ja ainult juhul, kui teisi ravimeetodeid ei ole võimalik kasutada.
English: Levetiracetam(oral solution) - Medication errors associated with accidental overdose (EPITT no 10519)
Estonian: Levetiratsetaam (suukaudne lahus) - juhusliku üleannustamisega seotud ravivead (EPITT nr 10519)
English: Adopted at the 26-29 September 2016 PRAC
Estonian: Vastu võetud ravimiohutuse riskihindamise komitee 26.-29. septembri 2016 koosolekul
English: • Stomach pain, anorexia, nausea, vomiting, fever, malaise, fatigue, jaundice, dark urine, putty or mastic coloured stools or itching.
Estonian: • kõhuvalu, isutus, iiveldus, oksendamine, palavik, halb enesetunne, väsimus, nahakollasus,
English: Package leaflet (except for products for external use on the skin) 2 - What you need to know before you use metronidazole Warnings and precautions
Estonian: Pakendi infoleht (v.a nahal välispidiseks kasutamiseks mõeldud ravimvormid) 2 - Mida on vaja teada enne metronidasooli kasutamist Hoiatused ja ettevaatusabinõud
English: Liver function tests must be performed just prior to the start of therapy, throughout and after end of treatment until liver function is within normal ranges, or until the baseline values are reached.
Estonian: Maksafunktsiooni analüüse tuleb teha vahetult enne ravi algust, ravi ajal ja pärast ravi lõppu seni, kuni maksafunktsioon on normaliseerunud või kuni saavutatakse uuesti ravieelsed analüüside tulemused.
English: When you will first start taking Keppra, your doctor will prescribe you a lower dose during 2 weeks before giving you the lowest general dose.
Estonian: Keppra-ravi alustamisel määrab arst teile kaheks nädalaks väiksema annuse, enne kui ta määrab teile väikseima tavalise annuse.
English: If the liver function tests become markedly elevated during treatment, the drug should be discontinued.
Estonian: Kui ravi ajal tekib maksanäitajate väärtuste oluline tõus, tuleb ravi katkestada.
English: Patients with Cockayne syndrome should be advised to immediately report any symptoms of potential liver injury to their physician and stop taking metronidazole.
Estonian: Cockayne'i sündroomiga patsiente tuleb juhendada, et kui neil tekivad võimaliku maksakahjustuse mis tahes sümptomid, tuleb neil sellest oma arstile kohe teatada ja metronidasooli võtmine lõpetada.
English: Dose in children 6 months and older weighing less than 50 Kg Dose in infants (6 to 23 months), children (2 to 11 years) and adolescents (12 to 17 years) weighing less than 50 kg:
Estonian: Annus 6-kuustele ja vanematele lastele kehakaaluga vähem kui 50 kg Annus imikutele (6...23 kuud), lastele (2...11-aastased) ja noorukitele (12...17-aastased) kehakaaluga alla 50 kg:
English: Metronidazole - Severe hepatic and neurologic toxicity in patients with Cockayne syndrome (EPITT no 18663)
Estonian: Metronidasool - raske maksatoksilisus ja neuroloogiline toksilisus Cockayne'i sündroomiga patsientidel (EPITT nr
English: If you are affected by Cockayne syndrome, your doctor should also monitor your liver function frequently while you are being treated with metronidazole and afterwards.
Estonian: Kui teil on Cockayne'i sündroom, peab arst metronidasoolravi ajal ja pärast seda pidevalt jälgima teie maksafunktsiooni.
English: Keppra is taken twice daily, in two equally divided doses, each individual dose being measured between 5 ml (500mg) and 15 ml (1500mg).
Estonian: ravimit Keppra võetakse kaks korda ööpäevas kahes võrdses annuses, kusjuures iga mõõdetud üksikannus on 5 ml (500 mg) kuni 15 ml (1500 mg).
English: Summary of product characteristics (except for products for external use on the skin)
Estonian: Ravimi omaduste kokkuvõte (v.a nahal välispidiseks kasutamiseks mõeldud ravimvormid)
English: Method of administration:
Estonian: Manustamisviis
English: The exact quantity of oral solution formulation should be delivered using the syringe provided in the cardboard box.
Estonian: Täpne suukaudse lahuse kogus määrata karbis leiduva süstla abil.
English: Dose in children 6 months and older weighing less than 50 kg: Weight
Estonian: Annus 6-kuustele ja vanematele lastele kehakaaluga vähem kui 50 kg Kehamass
English: General dose: Keppra is taken twice daily, in two equally divided doses, each individual dose being measured between 0.07 ml (7mg) and 0.21 ml (21mg), per kg bodyweight of the infant.
Estonian: Tavaline annus: ravimit Keppra võetakse kaks korda ööpäevas kahes võrdses annuses, kusjuures iga mõõdetud üksikannus on 0,07 ml (7 mg) kuni 0,21 ml (21 mg) imiku kehamassi iga kilogrammi kohta.
English: Dose in adults and adolescents (12 to 17 years) weighing 50 kg or more: Measure the appropriate dosage using the 10 ml syringe included in the package for patients of 4 years and above.
Estonian: Annus täiskasvanutele ja noorukitele (12-17-aastased)l, kelle kehamass on vähemalt 50 kg 4-aastastele ja vanematele patsientidele mõõtke õige annus välja pakendis oleva 10 ml süstla abil.
English: Dose in infants (1 month to less than 6 months): Weight
Estonian: Annus imikutele (1-kuused kuni vähem kui 6-kuused) Kehamass
English: General dose: between 0.14 ml (14 mg) and 0.42 ml (42 mg) per kg bodyweight each day, divided in 2 intakes per day.
Estonian: Tavaline annus on vahemikus 0,14 ml (14 mg) kuni 0,42 ml (42 mg) kehakaalu kg kohta iga päev jagatuna kaheks annuseks.
English: General dose: between 0.2 ml (20 mg) and 0.6 ml (60 mg) per kg bodyweight each day, divided in 2 intakes per day.
Estonian: Tavaline annus on vahemikus 0,2 ml (20 mg) kuni 0,6 ml (60 mg) kehakaalu kg kohta iga päev jagatuna kaheks annuseks.
English: Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use.
Estonian: Metronidasooli sisaldavate süsteemselt manustatavate ravimvormide kasutamisel on Cockayne'i sündroomiga patsientidel teatatud väga kiiresti pärast ravi algust tekkinud raske hepatotoksilisuse / ägeda maksapuudulikkuse, sealhulgas surmlõppega, juhtudest.
English: Take the oral solution following your doctor's instructions.
Estonian: Keppra suukaudse lahuse manustamisel jälgige arsti soovitusi.
English: General dose: Keppra is taken twice daily, in two equally divided doses, each individual dose being measured between 0.1 ml (10mg) and 0.3 ml (30mg), per kg bodyweight of the child. (see table below for dose examples).
Estonian: Tavaline annus: ravimit Keppra võetakse kaks korda ööpäevas kahes võrdses annuses, kusjuures iga mõõdetud üksikannus on 0,1 ml (10 mg) kuni 0,3 ml (30 mg) lapse kehamassi iga kilogrammi kohta.
English: General dose: between 10 ml (1000 mg) and 30 ml (3,000 mg) each day, divided in 2 intakes per day.
Estonian: Tavaline annus: 10 ml (1000 mg) kuni 30 ml (3000 mg) annus iga päev, jagatuna kaheks annuseks.
English: General dose: between 10 ml (1,000 mg) and 30 ml (3,000 mg) each day, divided in 2 intakes per day.
Estonian: Tavaline annus: 10 ml (1 000 mg) kuni 30 ml (3000 mg) annus iga päev, jagatuna kaheks annuseks.
English: Cases of severe liver toxicity/acute liver failure, including cases with a fatal outcome, in patients with Cockayne syndrome have been reported with product containing metronidazole.
Estonian: Cockayne'i sündroomiga patsientidel on metronidasooli sisaldavate ravimite kasutamisel teatatud raske maksatoksilisuse / ägeda maksapuudulikkuse, sealhulgas surmaga lõppenud, juhtudest.
English: For infants 1 month to less than 6 months, measure the appropriate dosage using the 1 ml syringe included in the package.
Estonian: Annus imikutele (1-kuused kuni vähem kui 6-kuused) Annus 1- kuni vähem kui 6-kuustele imikutele: mõõtke õige annus välja pakendisse lisatud 1 ml süstla abil.
English: Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/130)
Estonian: Direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse (EMEA/V/A/130) tulemused
English: The European Commission issued a decision on 20 September 2019.
Estonian: Euroopa Komisjon tegi otsuse 20. septembril 2019.
English: Why were veterinary medicines containing tylosin reviewed?
Estonian: Miks tülosiini sisaldavad veterinaarravimid läbi vaadati?
English: The full changes made to the product information are detailed in Annex III of the CVMP opinion under 'All documents'.
Estonian: Täielik ülevaade ravimiteabe muudatustest on veterinaarravimite komitee arvamuse III lisa jaotises „Kõik dokumendid“.
English: Tylosin is a macrolide antibiotic used mainly to treat infections caused by bacteria known as Grampositive bacteria.
Estonian: Tülosiin on makroliidantibiootikum, mida kasutatakse peamiselt grampositiivsete bakterinfektsioonide raviks.
English: The Committee concluded that the injection should be divided over two injection sites (maximum 2.5 ml injection volume per injection site).
Estonian: Komitee järeldas, et süstitav ravimi kogus tuleb jagada kahe süstekoha vahel (maksimaalselt 2,5 ml/süstekoht).
English: The CVMP recommended the variation of the marketing authorisations for these veterinary medicines.
Estonian: Veterinaarravimite komitee soovitas muuta nende veterinaarravimite müügilube.
English: Veterinary medicines containing tylosin are used in adult cattle, calves, pigs, sheep and goats and are given by injection into the muscle.
Estonian: Tülosiini sisaldavaid veterinaarravimeid kasutatakse täiskasvanud veistel, vasikatel, sigadel, lammastel ja kitsedel ning neid manustatakse intramuskulaarse süstega (lihasesse).
English: The Dutch authority considered that the withdrawal periods for sheep in the EU might not be adequate to ensure consumer safety, noting that withdrawal periods differed across the EU: from 8 to 42 days for sheep meat and offal and from 4 to 7 days for sheep milk.
Estonian: Madalmaade ravimiamet pidas võimalikuks, et lammaste keeluajad ELis ei ole piisavad tarbijaohutuse tagamiseks, märkides, et ELis kasutati eri keeluaegu: lambaliha ja -rupsi korral 8-42 päeva ning lambapiima korral 4-7 päeva.
English: Therefore, the CVMP concluded that the benefit-risk balance for the veterinary medicine Tilocen is not favourable for sheep and recommended a change to its marketing authorisation to remove any reference to use in sheep.
Estonian: Seepärast järeldas veterinaarravimite komitee, et veterinaarravimi Tilocen kasulikkuse ja riski suhe ei ole lammaste puhul soodne ning soovitas muuta ravimi müügiluba, et eemaldada kõik viited lammastel kasutamise kohta.
English: Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that, for 49 out of 50 products, those containing benzyl alcohol and propylene glycol as a non-active ingredient, the withdrawal periods for meat and offal from treated sheep should be 42 days, while the withdrawal periods for milk from treated sheep should be 108 hours.
Estonian: Praegu kättesaadavate andmete hindamise ja teaduslike arutelude põhjal järeldas veterinaarravimite komitee, et 49 ravimit 50st, mis sisaldavad mitteaktiivse koostisosana bensüülalkoholi ja propüleenglükooli, peab ravitud lammaste liha ja rupsi keeluaeg olema 42 päeva ning ravitud lammaste piima keeluaeg peab olema 108 tundi.
English: For one medicine, Tilocen, which contains the non-active ingredient polyethylene glycol 400, there were no data available that could be used to set adequate withdrawal periods in sheep.
Estonian: Ühe ravimi korral (Tilocen), mis sisaldab mitteaktiivse koostisosana ainet polüetüleenglükool 400, puudusid kättesaadavad andmed, mida saaks kasutada piisava keeluaja määramiseks lammastel.
English: In addition, cattle may also be treated by injection given slowly into a vein.
Estonian: Peale selle võib veiste ravimisel kasutada ka ravimi aeglast veeni süstimist.
English: On 28 September 2018, the Dutch medicines authority requested that the CVMP review all available data and recommend withdrawal periods for milk, meat and offal from sheep treated with injectable veterinary medicines containing tylosin.
Estonian: 28. septembril 2018 taotles Madalmaade ravimiamet, et veterinaarravimite komitee vaataks läbi kõik kättesaadavad andmed ja soovitaks tülosiini sisaldavate süstitavate ravimitega ravitud lammaste liha, rupsi ja piima keeluajad.
English: However, for one medicine, Tilocen, the Committee concluded that there were insufficient data to determine the withdrawal period and that it should therefore no longer be used in sheep.
Estonian: Ühe ravimi (Tilocen) kohta järeldas komitee siiski, et keeluaja määramise andmed on ebapiisavad ja ravimit ei tohi seetõttu enam lammastel kasutada.
English: On 20 June 2019, the European Medicines Agency completed a review of the withdrawal periods for injectable veterinary medicines containing tylosin when used in sheep.
Estonian: Euroopa Ravimiamet lõpetas 20. juunil 2019 lammastel kasutatavate tülosiini sisaldavate süstitavate veterinaarravimite keeluaegade läbivaatamise.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that for some of these medicines, the maximum injection volume per site and the withdrawal periods for sheep meat, offal and milk should be changed.
Estonian: Ameti veterinaarravimite komitee järeldas, et nendest ravimitest mõne korral tuleb muuta maksimumruumala süstekoha kohta ning lambaliha, -rupsi ja -piima keeluaegu.
English: The CVMP reviewed available data on residue depletion, which indicates how long a medicine takes to fall below maximum residue limits (MRLs) in the animal's body.
Estonian: Veterinaarravimite komitee vaatas läbi kättesaadavad andmed jääkide ammendumise kohta (aeg, kuni ravimi sisaldus looma organismis väheneb alla jääkide piirnormi), sealhulgas andmed ettevõtetelt ja avaldatud kirjandusest.
English: This summary was last updated in 10-2014
Estonian: Kokkuvõtte viimane uuendus: 10-2014.
English: Other information about Corbilta
Estonian: Muu teave Corbilta kohta
English: What measures are being taken to ensure the safe and effective use of Corbilta?
Estonian: Mis meetmed võetakse, et tagada Corbilta ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Corbilta is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Corbilta võimalikult ohutu kasutamine.
English: Entacapone has been authorised in the European Union (EU) as Comtess/Comtan since 1998.
Estonian: Entakapoon on ravimina Comtess/Comtan Euroopa Liidus heaks kiidetud alates 1998. aastast.
English: All of the tablets contain 200 mg entacapone.
Estonian: Kõik tabletid sisaldavad 200 mg entakapooni.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Corbilta on 11 November 2013.
Estonian: Euroopa Komisjon andis Corbilta müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 11 novembril
English: The full EPAR for Corbilta can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Corbilta kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Levodopa / carbidopa / entacapone
Estonian: Corbilta levodopa/karbidopa/entakapoon
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Corbilta's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Corbilta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: Why is Corbilta approved?
Estonian: Miks Corbilta heaks kiideti?
English: The company that makes Stalevo has agreed that its scientific data can be used for Corbilta (‘informed consent').
Estonian: Stalevo tootja on andnud nõusoleku, et tema teaduslikke andmeid võib kasutada ka Corbilta toetuseks (teabel põhinev nõusolek).
English: This medicine is the same as Stalevo, which is already authorised in the European Union (EU).
Estonian: See ravim on samane Stalevoga, millel juba on Euroopa Liidus müügiluba.
English: What is Corbilta and what is it used for?
Estonian: Mis on Corbilta ja milleks seda kasutatakse
English: This is a summary of the European public assessment report (EPAR) for Corbilta.
Estonian: See on ravimi Corbilta Euroopa avaliku hindamisaruande kokkuvõte.
English: Fluctuations happen when the effects of the medication wear off and symptoms re-emerge.
Estonian: Ebakindlad sümptomid tekivad, kui ravimiannuse toime lõpeb ja sümptomid ilmnevad uuesti.
English: What are the risks associated with Corbilta?
Estonian: Mis riskid Corbiltaga kaasnevad?
English: The maximum daily dose of Corbilta is 10 tablets, except for the tablets containing 175 mg levodopa and 43.75 mg carbidopa, for which the maximum daily dose is eight tablets, and those containing 200 mg levodopa and 50 mg carbidopa, for which the maximum daily dose is seven tablets.
Estonian: Ravimi Corbilta suurim ööpäevane annus on 10 tabletti, välja arvatud 175 mg levodopat ja 43,75 mg karbidopat sisaldavad tabletid, mille suurim ööpäevane annus on 8 tabletti, ning 200 mg levodopat ja 50 mg karbidopat sisaldavad tabletid, mille suurim ööpäevane annus on 7 tabletti.
English: Levodopa is converted into dopamine in the brain.
Estonian: Levodopa muutub ajus dopamiiniks.
English: The use of combinations of levodopa and carbidopa is well established, having being in use since the mid1970s.
Estonian: Levodopa ja karbidopa kombinatsioone on kasutatud 1970. aastate keskpaigast ja nende kasutus on hästi tõestatud.
English: Corbilta must not be used in patients with:
Estonian: Ravimit Corbilta ei tohi kasutada patsiendid, kellel on järgmised haigused:
English: The strength of Corbilta that the patient should use is based on the amount of levodopa they need to control their symptoms.
Estonian: Ravimi Corbilta tugevus, mida patsient peab kasutama, sõltub sümptomite leevendamiseks vajalikust levodopa kogusest.
English: Corbilta is used when these fluctuations cannot be treated with the standard combination alone.
Estonian: Ravimit Corbilta kasutatakse juhul, kui sümptomite ebakindlust ei saa ravida ainult standardse ravimikombinatsiooniga.
English: Corbilta is a medicine that contains three active substances: levodopa, carbidopa and entacapone.
Estonian: Corbilta on ravim, mis sisaldab kolme toimeainet: levodopat, karbidopat ja entakapooni.
English: Corbilta is available as a range of tablets in seven strengths, containing 50 to 200 mg levodopa and 12.5 to 50 mg carbidopa.
Estonian: Ravimit Corbilta turustatakse seitsme eri tugevusega tablettidena, mis sisaldavad 50 kuni 200 mg levodopat ja 12,5 kuni 50 mg karbidopat.
English: It is not intended to provide practical advice on how to use Corbilta.
Estonian: Hindamisaruandes ei anta Corbiltai kasutamise praktilisi nõuandeid.
English: Having all three substances in the same tablet can lower the number of tablets patients have to take and help them stick to their treatment.
Estonian: Kõigi kolme toimeaine sisaldumine ühes tabletis aitab vähendada patsiendi võetavate tablettide arvu ja järgida raviskeemi.
English: Corbilta must not be used together with other medicines that belong to the group ‘monoamine oxidase inhibitors' (a type of antidepressant).
Estonian: Corbiltat ei tohi kasutada koos teiste monoaminooksüdaasi inhibiitorite (antidepressantide liik) rühma ravimitega.